Rallybio signs definitive all-stock merger with Candid Therapeutics

 

 backed by $505 million private financing

• Combined company will be renamed Candid Therapeutics and trade on Nasdaq under ticker CDRX after closing.
• Current Rallybio shareholders are expected to own about 3.65% of the combined company at closing.
• Rallybio shareholders will also receive contingent value rights in connection with the Candid merger transaction.

https://finviz.com/quote.ashx?t=RLYB&p=d